1. 1) U.S. Food and Drug Administration, “Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications.”: ‹https://www.fda.gov/news-events/press-announcements/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications›, cited 31 January, 2021.
2. 2) ICH. “ICH HARMONISED GUIDELINE ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK M7(R1).” cited 11 February, 2021.
3. 3) European Medicines Agency, “Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities.”: ‹https://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities›, cited 11 February, 2021.
4. 4) Ministry of Health Labour and Welfare of Japan, “Notification: setting of interim limits for NDMA and NDEA in Sartan drugs.”: ‹https://www.pmda.go.jp/files/000226684.pdf›, cited 11 February, 2021.
5. 5) U.S. Food and Drug Administration, “Statement on new testing results, including low levels of impurities in ranitidine drugs.”: ‹https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs›, cited 11 February, 2021.